These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational study. Martens RJH, Broers NJH, Canaud B, Christiaans MHL, Cornelis T, Gauly A, Hermans MMH, Konings CJAM, van der Sande FM, Scheijen JLJM, Stifft F, Wirtz JJJM, Kooman JP, Schalkwijk CG. PLoS One; 2019; 14(8):e0221058. PubMed ID: 31408493 [Abstract] [Full Text] [Related]
23. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G, Collaborative Study Group. Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053 [Abstract] [Full Text] [Related]
24. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054 [Abstract] [Full Text] [Related]
25. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jørgensen K, Bangstad HJ, Hanssen KF. Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757 [Abstract] [Full Text] [Related]
27. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL. Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447 [Abstract] [Full Text] [Related]
28. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. Semba RD, Gebauer SK, Baer DJ, Sun K, Turner R, Silber HA, Talegawkar S, Ferrucci L, Novotny JA. J Nutr; 2014 Jul; 144(7):1037-42. PubMed ID: 24744309 [Abstract] [Full Text] [Related]
29. Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. Lamb LS, Alfonso H, Norman PE, Davis TME, Forbes J, Müench G, Irrgang F, Almeida OP, Golledge J, Hankey GJ, Flicker L, Yeap BB. J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4224-4231. PubMed ID: 30137355 [Abstract] [Full Text] [Related]
30. Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG. Cardiovasc Diabetol; 2013 Oct 17; 12():149. PubMed ID: 24134530 [Abstract] [Full Text] [Related]
32. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, Jardack P, Traber MG, Ferrucci L, Arab L. Eur J Clin Nutr; 2012 Jan 17; 66(1):3-9. PubMed ID: 21792213 [Abstract] [Full Text] [Related]
34. Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study. Jiao L, Stolzenberg-Solomon R, Zimmerman TP, Duan Z, Chen L, Kahle L, Risch A, Subar AF, Cross AJ, Hollenbeck A, Vlassara H, Striker G, Sinha R. Am J Clin Nutr; 2015 Jan 17; 101(1):126-34. PubMed ID: 25527756 [Abstract] [Full Text] [Related]
35. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. Semba RD, Beck J, Sun K, Egan JM, Carlson OD, Varadhan R, Ferrucci L. J Nutr Health Aging; 2010 Aug 17; 14(7):507-13. PubMed ID: 20818463 [Abstract] [Full Text] [Related]
37. Plasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts. Lamprea-Montealegre JA, Arnold AM, McCLelland RL, Mukamal KJ, Djousse L, Biggs ML, Siscovick DS, Tracy RP, Beisswenger PJ, Psaty BM, Ix JH, Kizer JR. J Am Heart Assoc; 2022 Aug 02; 11(15):e024012. PubMed ID: 35904195 [Abstract] [Full Text] [Related]
38. Urinary excretion of amino acids and their advanced glycation end-products (AGEs) in adult kidney transplant recipients with emphasis on lysine: furosine excretion is associated with cardiovascular and all-cause mortality. Baskal S, Post A, Kremer D, Bollenbach A, Bakker SJL, Tsikas D. Amino Acids; 2021 Nov 02; 53(11):1679-1693. PubMed ID: 34693489 [Abstract] [Full Text] [Related]
39. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. Kizer JR, Benkeser D, Arnold AM, Djousse L, Zieman SJ, Mukamal KJ, Tracy RP, Mantzoros CS, Siscovick DS, Gottdiener JS, Ix JH. J Clin Endocrinol Metab; 2013 Jan 02; 98(1):255-63. PubMed ID: 23162097 [Abstract] [Full Text] [Related]
40. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study. Linssen PB, Henry RM, Schalkwijk CG, Dekker JM, Nijpels G, Brunner-La Rocca HP, Stehouwer CD. Diab Vasc Dis Res; 2016 Jul 02; 13(4):278-85. PubMed ID: 27190078 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]